Intelligence Platform
Surface licensing opportunities from Chinese regulatory filings, clinical trials, and financial data — months before traditional channels.
25
Companies
1,000+
Molecules
5
Data Sources
1h
Sync Cadence
Platform
01
Scored feed of Chinese oncology molecules ranked by BD relevance. Filter by phase, modality, target, and therapeutic area.
02
Auto-generated profiles with financials, pipeline depth, regulatory history, and deal track record.
03
Real-time notifications for new filings, approvals, trial milestones, and deal announcements.
Sources
SEC EDGAR
20-F, 10-K annual reports and 6-K current reports for US-listed Chinese biotechs.
HKEX
Annual and interim reports from HK-listed biopharma companies under Chapter 18A.
NMPA / CDE
IND/NDA filings, approval decisions, and clinical trial registrations from China's drug authority.
ChiCTR
China-registered clinical trials with enrollment data, endpoints, and site locations.
ClinicalTrials.gov
Global trial registrations cross-referenced with Chinese sponsor companies.
Workers AI
LLM-powered extraction of deal terms, pipeline updates, and financial data from raw filings.
KirinBD surfaces licensing signals from Chinese biopharma data before they hit the conference circuit.